Citryll's Groundbreaking Series B Funding: Advancing Immune Disorder Therapy
Deal News | Dec 09, 2024 | Biogeneration Ventures (BGV)
Citryll, a biotechnology company focused on developing novel therapies for immune-mediated inflammatory disorders, has successfully completed a Series B funding round, raising €85 million. The financing round was led by Biogeneration Ventures (BGV), alongside other investors. The capital will be utilized to advance Citryll's innovative NET-targeting therapy. This approach aims to treat inflammatory disorders by targeting Neutrophil Extracellular Traps (NETs), a known contributor to these diseases. The funding is a significant boost for Citryll, enabling it to progress its therapeutic candidates through clinical development and to potentially offer new, effective treatments for patients suffering from these debilitating conditions.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- The Netherlands – Biogeneration Ventures is based in The Netherlands, indicating its geographic relevance.
- Europe – The funding currency is the Euro, which commonly associates with European countries.
Industry
- Biotechnology – The article pertains to Citryll, a biotechnology firm developing novel therapies for immune-mediated inflammatory disorders.
- Healthcare – The focus on developing therapies for inflammatory diseases places this within the healthcare sector.
- Private Equity – Biogeneration Ventures, a private equity firm, is a leading participant in the mentioned funding round.
Financials
- €85 million – The amount raised by Citryll in its Series B funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Citryll | Target | Company | Biotechnology company focused on NET-targeting therapies for immune-mediated inflammatory disorders. |
| Biogeneration Ventures (BGV) | Investor | PE Firm | Lead investor in Citryll's Series B funding round. |